Cargando…
SAT-474 Giant Prolactinoma Case Series Assessing Response on Initial Dose of Cabergoline
Background: Giant prolactinomas (GPs) are rare representing 2-3% of prolactinomas and only ~ 0.5% of all pituitary tumors. Various definitions have been proposed for GP but commonly accepted criteria is tumor dimension of ≥4 cm. GP is often associated with very high prolactin (PRL) ranging 1,000 -10...
Autores principales: | Madan Paramasivan, Ameena, Marouf, Sarah, Raghunathan, Sapna, Shoakazemi, Alireza, Pollock, Jonathan, Chawda, Sanjiv, Stojanovic, Nemanja, Drincic, Andjela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552231/ http://dx.doi.org/10.1210/js.2019-SAT-474 |
Ejemplares similares
-
SUN-406 Complete Recovery of Central Diabetes Insipidus Associated with Isolated Stalk Thickening in a Neurosarcoidosis Patient
por: Madan Paramasivan, Ameena, et al.
Publicado: (2019) -
SAT-246 A Case of Cabergoline Induced Pituitary Apoplexy in a Patient with Prolactinoma
por: Ahuja, Ashim
Publicado: (2020) -
SAT-270 Priapism Secondary to Cabergoline
por: Amir, Maryam, et al.
Publicado: (2020) -
FRI322 Lack Of Tumor Size Change With Long-term Cabergoline For Prolactinoma
por: Bendaram, Snigdha Reddy, et al.
Publicado: (2023) -
FRI321 Aggressive Prolactinoma Empirically Treated With Cabergoline Leading To Rapid CSF Leak
por: Yau, Alice, et al.
Publicado: (2023)